Loss of Exclusivity vs. Patent Expiry: What's the Difference?
Published April 6, 2026 · USPTO & FDA data
Loss of exclusivity (LOE) and patent expiry are related but distinct concepts, and confusing them leads to incorrect predictions about when generic drugs will actually reach the market. Patent expiry is when a specific patent term ends. Loss of exclusivity is when all forms of market protection expire, including patents, regulatory exclusivity, and data exclusivity. LOE is the date that determines when generics can enter.
The Core Distinction
A branded drug is typically protected by multiple overlapping layers of intellectual property and regulatory protection. These layers can expire at different times:
- Patents protect specific inventions: the molecule, a formulation, a manufacturing process, a method of treatment. Each patent has its own expiration date, typically 20 years from its filing date.
- Regulatory exclusivity is granted by the FDA independently of patents. It prevents the agency from approving (or sometimes even reviewing) generic or biosimilar applications during the exclusivity period, regardless of patent status.
- Data exclusivity prevents generic applicants from relying on the innovator's clinical trial data to support their own applications for a fixed period after approval.
Loss of exclusivity is the date when the last of these protections falls away. Only then can a generic or biosimilar competitor legally enter the market.
Side-by-Side Comparison
| Dimension | Patent Expiry | Loss of Exclusivity (LOE) |
|---|---|---|
| Definition | The date a specific patent term ends | The date all market protections end |
| Legal basis | Patent law (35 U.S.C.) | Combination of patent law and FDA regulatory law (21 CFR) |
| Scope | Covers one patent; a drug may have dozens | Covers all protections: every patent plus every exclusivity |
| Duration | 20 years from filing date (plus extensions) | Variable; depends on which protection expires last |
| Impact on generics | Removes one barrier; others may remain | Removes the final barrier; generics can launch |
| Example | A drug's composition patent expires in 2027 | The same drug has orphan exclusivity until 2029, so LOE is 2029 |
Why the Dates Often Differ
Consider a biologic drug approved in 2018. Its earliest patent was filed in 2010 and expires in 2030. But as a biologic, it has 12 years of reference product exclusivity from approval, which runs until 2030 as well. If the company also obtained pediatric exclusivity (+6 months), the LOE date becomes mid-2030, even though the key patent expires at the start of 2030.
In the opposite scenario, a drug might have NCE exclusivity that expired in 2023 but still has active patents running until 2028. Here the patents outlast the regulatory exclusivity, so LOE is 2028. The point is that LOE is always the later of the two.
Types of Regulatory Exclusivity
Understanding which exclusivities are in play is essential for predicting the true LOE date:
- New Chemical Entity (NCE) exclusivity (5 years): Granted when the FDA approves a drug containing an active ingredient that has never been approved before. During this period, the FDA will not accept any ANDA referencing the drug.
- Orphan drug exclusivity (7 years): Granted for drugs treating rare diseases (fewer than 200,000 patients). Blocks FDA approval of the same drug for the same indication, even if no patents exist.
- Biologic reference product exclusivity (12 years): Under the BPCIA, the FDA cannot approve a biosimilar application for 12 years after the reference biologic was approved. Biosimilar applications cannot even be submitted for 4 years.
- Pediatric exclusivity (+6 months): Added on top of all existing patents and exclusivities when the manufacturer completes FDA-requested pediatric studies.
- New clinical investigation exclusivity (3 years): Granted for a new use, dosage form, or combination supported by new clinical trials. Narrower than NCE exclusivity.
Why This Matters for Investors and Analysts
Financial models that use patent expiration dates instead of LOE dates will systematically overestimate how quickly generic competition arrives. For a biologic with 12 years of reference product exclusivity, the LOE date can be years after the last patent expires. Conversely, for an older small-molecule drug, patents may extend well beyond regulatory exclusivity. Accurate valuation requires tracking both timelines and using the later date.
Why This Matters for Patients
Patients waiting for affordable generic alternatives need to watch the LOE date, not the patent date. A drug whose patents have expired may still be years away from generic availability if regulatory exclusivity remains in effect. This is especially relevant for biologic drugs, where the 12-year exclusivity period often determines the timeline for biosimilar competition.
Frequently Asked Questions
What does loss of exclusivity mean?
Loss of exclusivity (LOE) is the date when all forms of market protection for a branded drug have ended, including patents, regulatory exclusivity, and data exclusivity. LOE is the date that actually matters for generic or biosimilar entry because it marks the earliest point at which a competitor can legally launch a competing product.
Why is LOE different from patent expiry?
A drug may have multiple overlapping protections: patents on the molecule, formulation, and method of use, plus FDA-granted regulatory exclusivity (NCE, orphan, biologic, pediatric). Patent expiry removes one layer of protection, but if regulatory exclusivity is still active, generics still cannot enter. LOE occurs when the last remaining protection of any type expires.
When do generics actually enter the market?
Generics can enter the market at or after loss of exclusivity, but in practice there is often a lag. Generic companies must file abbreviated applications (ANDAs or aBLAs) and receive FDA approval, which can take 1-3 years. The first generic filer under the Hatch-Waxman Act receives 180 days of generic exclusivity, during which no other generics can launch. For biosimilars, the approval timeline is typically longer than for small-molecule generics.
What is regulatory exclusivity?
Regulatory exclusivity is a period of market protection granted by the FDA independent of patents. It prevents the FDA from approving or sometimes even accepting generic or biosimilar applications during the exclusivity period. Types include new chemical entity exclusivity (5 years), orphan drug exclusivity (7 years), biologic reference product exclusivity (12 years), and pediatric exclusivity (additional 6 months).
About This Data
Patent data from USPTO PatentsView API. Exclusivity data from the FDA Orange Book and Purple Book. Regulatory exclusivity rules per the Hatch-Waxman Act and BPCIA. See our methodology.